We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck announced that it is ending a phase 3 study evaluating its immunotherapy bintrafusp alfa in patients with stage IV non-small-cell lung cancer, following disappointing efficacy results. Read More
The FDA is calling for risk assessments by cell and gene therapy (CGT) manufacturers to minimize the potential for transmitting the SARS-CoV-2 virus through their products, according to a new straight-to-final guidance released yesterday. Read More
Under the Biden administration, the U.S. will join the World Health Organization (WHO)’s COVAX program and may potentially contribute billions of dollars toward providing access to COVID-19 vaccines in low- and middle-income nations, though it’s not yet known how much money the president will pledge. Read More
Pfizer and BioNTech released new study results yesterday indicating their COVID-19 vaccine would likely induce immunity for all 10 mutations on the spike protein of the SARS-CoV-2 viral strain identified in the UK, but other research suggests the vaccine might not be effective against new variants. Read More
A new survey has found that interactions between U.S. family medicine residencies and the pharma industry in 2019 continued a decade-long downward trend. Read More